 Crinetics Pharmaceuticals NASDAQ:CRNX was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Friday, Zacks.com reports. The brokerage currently has a 20.00 price target on the stock. Zacks Investment Researchs target price suggests a potential upside of 12.80 from the companys current price. According to ... 